19.12.2012
MagForce aims to raise up to €33.5 million
Berlin, Germany, December 19, 2012 – MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the field of nanomedicine with a focus on oncology, today announced that the Company, with the approval of the Supervisory Board, has resolved a restructuring plan to safeguard MagForce’s ...
01.10.2012
MagForce publishes half-year report
Berlin, Germany, October 1, 2012 – MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the field of nanomedicine with a focus on oncology, today announced the financial results for the first half of the 2012 fiscal year, ending June 30, 2012. Simultaneously, the company ...
01.10.2012
MagForce to radically enforce market setup strategy with new management team
Berlin, Germany, October 1, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with a focus on oncology, today announced additions to the management board and further measures to enforce commercialization of NanoTherm® therapy. Thus, focussing ...
17.08.2012
Dr. Jan zur Hausen elected to the Supervisory Board of MagForce AG
Berlin, Germany, August 17, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that Dr. Jan zur Hausen was unanimously elected to the company’s Supervisory Board at yesterday’s Annual General Meeting. He ...
29.06.2012
Magforce AG: Publication of Financial Results 2011
Berlin, Germany, June 29, 2012 – MagForce announces its financial results for the period from January 01, 2011 till December 31, 2011, on July 02, 2012. The annual report will be available on the corporate website on July 02, 2012, after close of trading.
22.06.2012
MagForce enters into preclinical research agreement to investigate NanoTherm® therapy in the gastrointestinal cancer field in the USA
Berlin, Germany, June 22, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that the Company has entered into a pre-clinical research agreement with Mayo Clinic (Rochester, MN), a leading US medical ...
